Johnson & Johnson Q3 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Chris Schott - JPMorgan - Analyst : Great. Thanks so much for the question. Maybe just one on talc here. I know there's still limited comments, but it seems as though the company's obviously made some advancements here into getting this behind the organization. Maybe just -- can you help us a little bit in terms of, from your perspective, next key steps to watch from here? And what is J&J's overall level of confidence that you have a path to resolve this in the relative near term for the story? Thanks so much.

Question: Larry Biegelsen - Wells Fargo Securities, LLC - Analyst : Good morning. Thanks for taking the question. Tim, on MedTech, maybe help us understand the impact of the one-time items in Q3, such as the ortho, SKU rationalization, how you're thinking about the impact from hurricanes in Q4. What gives you confidence you can deliver the high end of that 5% to 7% next year? Thanks for taking the question.

Question: Louise Chen - Cantor Fitzgerald - Analyst : Hi, thank you for taking my question here. I wanted to ask you how you see TREMFYA, JNJ-2113, and some of your other pipeline products coming together to replace sales loss to STELARA, and then take share from entrenched competitors. Thank you.

Question: Terence Flynn - Morgan Stanley & Co. LLC - Analyst : Great. Thanks so much for taking the question. Maybe just on the multiple myeloma portfolio, obviously, very nice growth in CARVYKTI this quarter. I know you spoke to some of the drivers, but just was wondering if you can elaborate on what you're seeing in the second-line setting at this point. And then as you look at TECVAYLI through the rest of this year into next year, what's it going to take to really see an acceleration in growth in this product? Or do we have to wait until we get to earlier lines of treatment here to see growth again in that franchise? Thank you.

Question: Danielle Antalffy - UBS - Analyst : Hey, good morning, everyone. Thanks so much for taking the question. Just a quick question on the EP business. I mean, obviously, that's very topical. You hadn't really seen much of a slowdown. I appreciate Q3 was probably arguably the first quarter where we had a more -- a full quarter of PFA launching. I guess, I'm just curious about what you think the underlying market is growing and where PFA is versus RF. And also, as we look ahead to 2025 and VARIPULSE, how that changes dynamics for J&J's EP business. Thanks so much.

Question: Shagun Singh - RBC Capital Markets Wealth Management - Analyst : Great. Thank you so much. I was hoping you could elaborate on the dynamics that you're seeing in the Asia-Pacific region in MedTech, specifically China. Could you quantify the headwinds? When do you expect it to normalize? And you did talk about China VBP and that it's expanded into additional provinces and products, so could you just elaborate on the impact there and how we should think about it in '25? Thank you.

Question: Vamil Divan - Guggenheim Securities LLC - Analyst : Thanks for taking my question. I have a question on the immunology side just on TREMFYA and STELARA. You mentioned the US sales for both those products were a little bit lighter than we were expecting. and you mentioned this unfavorable patient mix impacting the quarter. So I'm just curious if you can you just going a little more detail on what you're seeing for those products in the US specifically and this patient mix issues this quarter. So I'm just curious if you can just go into a little more detail on what you're seeing for those products in the US specifically. And is this patient mix issue sort of this quarter? Is it adjustments from prior quarters? And is there something specific to the Johnson & Johnson? Or is it maybe something broader to the immunology market? Thank you.

Question: Jayson Bedford - Raymond James - Analyst : Good morning. Maybe just a question for either Tim or Joe. Appreciate the color on MedTech, but the 5% bogey (inaudible) for the year still implies a decent acceleration in 4Q off a tougher comp. What gets better in 4Q? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 15, 2024 / 12:30PM, JNJ.N - Q3 2024 Johnson & Johnson Earnings Call And then just a quick clarification. The IV solutions dynamic from Helene, are you seeing an impact on volumes outside of Western North Carolina and Florida? Thanks.